Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that affects 1 in ~350 individuals. Genetic association studies have established ALS as a multifactorial disease with heritability estimated at ~61%, and recent studies show a prominent role for rare variation in its genetic architecture. To identify rare variants associated with disease onset we performed exome array genotyping in 4,244 cases and 3,106 controls from European cohorts. In this largest exome-wide study of rare variants in ALS to date, we performed single-variant association testing, gene-based burden, and exome-wide individual set-unique burden (ISUB) testing to identify single or aggregated rare variation that modifies disease risk. In single-variant testing no variants reached exome-wide significance, likely due to limited statistical power. Gene-based burden testing of rare non-synonymous and loss-of-function variants showed NEK1 as the top associated gene. ISUB analysis did not show an increased exome-wide burden of deleterious variants in patients, possibly suggesting a more region-specific role for rare variation. Complete summary statistics are released publicly. This study did not implicate new risk loci, emphasizing the immediate need for future large-scale collaborations in ALS that will expand available sample sizes, increase genome coverage, and improve our ability to detect rare variants associated to ALS.

Details

Title
Exome array analysis of rare and low frequency variants in amyotrophic lateral sclerosis
Author
Dekker, Annelot M 1 ; Diekstra, Frank P 1 ; Pulit, Sara L 1   VIAFID ORCID Logo  ; Tazelaar Gijs H P 1 ; van der Spek Rick A 1 ; Wouter, van Rheenen 1   VIAFID ORCID Logo  ; van Eijk Kristel R 1 ; Calvo, Andrea 2   VIAFID ORCID Logo  ; Brunetti, Maura 2 ; Damme Philip Van 3 ; Robberecht Wim 3 ; Hardiman Orla 4 ; McLaughlin, Russell 5 ; Chiò Adriano 2   VIAFID ORCID Logo  ; Sendtner, Michael 6   VIAFID ORCID Logo  ; Ludolph, Albert C 7 ; Weishaupt, Jochen H 7 ; Pardina Jesus S Mora 8 ; van den Berg Leonard H 1 ; Veldink, Jan H 1 

 University Medical Center Utrecht, Department of Neurology, Brain Center Rudolf Magnus, Utrecht, The Netherlands (GRID:grid.7692.a) (ISNI:0000000090126352) 
 University of Torino, Rita Levi Montalcini’ Department of Neuroscience, ALS Centre, Turin, Italy (GRID:grid.7605.4) (ISNI:0000 0001 2336 6580) 
 KU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology and Leuven, Research Institute for Neuroscience and Disease (LIND), Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884); VIB, Vesalius Research Center, Laboratory of Neurobiology, Leuven, Belgium (GRID:grid.11486.3a) (ISNI:0000000104788040); University Hospitals Leuven, Department of Neurology, Leuven, Belgium (GRID:grid.410569.f) (ISNI:0000 0004 0626 3338) 
 Academic Unit of Neurology, Trinity College Dublin, Trinity Biomedical Sciences Institute, Dublin, Ireland (GRID:grid.8217.c) (ISNI:0000 0004 1936 9705); Department of Neurology, Beaumont Hospital, Dublin, Ireland (GRID:grid.414315.6) (ISNI:0000 0004 0617 6058) 
 Population Genetics Laboratory, Smurfit Institute of Genetics, Trinity College Dublin, Dublin, Ireland (GRID:grid.8217.c) (ISNI:0000 0004 1936 9705) 
 University of Würzburg, Institute of Clinical Neurobiology, Würzburg, Germany (GRID:grid.8379.5) (ISNI:0000 0001 1958 8658) 
 Ulm University, Department of Neurology, Ulm, Germany (GRID:grid.6582.9) (ISNI:0000 0004 1936 9748) 
 ALS Unit, Hospital San Rafael, Madrid, Spain (GRID:grid.6582.9) 
Publication year
2019
Publication date
2019
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2207984662
Copyright
© The Author(s) 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.